CHO Plus, Inc. ( a leading developer of biopharmaceutical manufacturing technology, announced that U.S. Patent No. 12,252,713 was issued by the United States Patent and Trademark Office. The patent ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Why Norstella, Makersite, Satelytics, and Chainalysis are among Fast Company's Most Innovative Companies in data science for ...
Opinion
Oracle and NVIDIA Unveil Massive Collaboration for Accelerating AI Development and DeploymentOracle and NVIDIA are announcing a first-of-its-kind integration between NVIDIA accelerated computing and inference software with Oracle's AI infrastructure and generative AI services, making over 160 ...
AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...
Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...
Organizations can deploy OCI's 150+ AI and cloud services with NVIDIA accelerated computing and NVIDIA AI Enterprise in their data center, the public cloud, or at the edge. This offering provides an ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Sticking with AI agents, Nvidia also revealed it’s expanding its association with Oracle Corp. to bring agentic AI to Oracle ...
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
Plus Therapeutics shares are trading higher by 183% during Thursday's session. The company announced that the FDA accepted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback